New molecular targets for the treatment of neovascular age-related macular degeneration

  • Gian Marco Tosi Ophthalmology Unit of the Department of Medicine, Surgery and Neuroscience, University of Siena, Italy.
  • Marcella Barbarino Department of Medicine, Surgery and Neuroscience, University of Siena, Siena, Italy.
  • Maurizio Orlandini Department of Biotechnology, Chemistry and Pharmacy, University of Siena, Siena, Italy.
  • Federico Galvagni | federico.galvagni@gmail.com Department of Biotechnology, Chemistry and Pharmacy, University of Siena, Siena, Italy. http://orcid.org/0000-0003-1967-9554

Abstract

Age-related macular degeneration (AMD) is a progressive chronic disease that currently represents the leading cause of irreversible vision loss in the western world. Experimental and clinical evidence has demonstrated that vascular endothelial growth factor A (VEGF-A) plays an important role in promoting the choroidal neovascularization that characterizes the wet form of AMD. Intravitreal injection of anti- VEGF-A agents is the current treatment of choice for neovascular AMD (nAMD). These agents have brought about dramatic changes in the treatment of nAMD, but most patients require frequently repeated injections and regular long-term follow-up, with a significant percentage of them showing resistance to anti-VEGF-A drugs. Thus, the identification of additional therapies that could improve the treatment protocols is needed. There are numerous areas of investigation into new treatments, with increasing efforts being made to study drugs that address various targets along the angiogenic signaling cascade, or other pathways related to the onset of nAMD. The aim of the present review is to summarize and discuss promising new therapies and targets that have the potential to improve outcomes and to lengthen treatment durability, especially in patients with recalcitrant or recurrent forms of nAMD.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.

Author Biographies

Gian Marco Tosi, Ophthalmology Unit of the Department of Medicine, Surgery and Neuroscience, University of Siena
Ophthalmology Unit of the Department of Medicine, Surgery and Neuroscience
Marcella Barbarino, Department of Medicine, Surgery and Neuroscience, University of Siena, Siena

Department of Medicine, Surgery and Neuroscience

Maurizio Orlandini, Department of Biotechnology, Chemistry and Pharmacy, University of Siena, Siena

Department of Biotechnology,
Chemistry and Pharmacy

 

Federico Galvagni, Department of Biotechnology, Chemistry and Pharmacy, University of Siena, Siena

 

 

Published
2017-11-27
Info
Issue
Section
Review Articles
Keywords:
Choroidal neovascularization, Age-related macular degeneration, New molecular targets
Statistics
  • Abstract views: 787

  • PDF: 291
How to Cite
Tosi, G. M., Barbarino, M., Orlandini, M., & Galvagni, F. (2017). New molecular targets for the treatment of neovascular age-related macular degeneration. Translational Medicine Reports, 2(1). https://doi.org/10.4081/tmr.6819